Therapeutic challenges of acute bacterial exacerbation of chronic bronchitis

American Journal of Managed Care

Volumn 5, Issue 11 SUPPL., 1999, Pages

  Southard, John ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; BETA LACTAMASE; CEFIXIME; CEFPODOXIME; CEFPROZIL; CEFUROXIME; CIPROFLOXACIN; LORACARBEF; OFLOXACIN; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; CHRONIC BRONCHITIS; CIGARETTE SMOKING; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG PENETRATION; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 0032852147     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Chodosh S. Treatment of acute exacerbations of chronic bronchitis: State of the art. Am J Med 1991;91(suppl 6A):87S-91S.
2. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995;108:43S-52S.
3. Centers for Disease Control and Prevention. Number of selected chronic conditions per 1,000 persons, by age: United States, 1994. Available at: http://www.cdc. gov/nchswww/fastats/ce94t57.htm. Accessed July 22, 1998.
4. Ball P, Harris JM, Lowson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis. Q J Med 1995;88:61-68.
5. Ball P, Tillotson G, Wilson R. Chemotherapy for chronic bronchitis controversies. Presse Med 1995;24:189-194.
6. Wilson R. The pathogenesis and management of bronchial infections: The vicious circle of respiratory decline. Rev Contemp Pharmacother 1992;3:103-112.
7. Cole P, Wilson R. Host-microbial relationships in respiratory infection. Chest 1989;95(suppl):217S-221S.
8. Verghese A, Ismail HM. Acute exacerbations of chronic bronchitis: Preventing treatment failures and early reinfection. J Postgrad Med 1994;96:75-89.
9. Niederman MS. Acute exacerbations of chronic bronchitis: The role of infection and the selection of appropriate therapy. PCCU 1996;11:2-8.
10. Zeckel ML, Jacobson KD, Guerra FJ, Therasse DG, Farlow D. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Ther 1992;14:214-229.
11. Roberts D, Cole P. Effect of tobacco and nicotine on growth of Haemophilus influenzae in vitro. J Clin Pathol 1979;32:728-731.
12. File TM Jr. Etiology and incidence of community-acquired pneumonia. IDCP 1996;5(suppl 4):S127-S135.
13. Bartlett JG. Assessment of response to antimicrobial therapy and time to discharge in patients hospitalized with community-acquired pneumonia. IDCP 1996;5(suppl 4):S148-S153.
14. Scannapieco FA, Papandonatos GD, Dunford RG. Associations between oral conditions and respiratory disease in a national sample survey population. Ann Periodontol 1998;3:251-256.
15. du Moulin GC, Peterson DG, Hedley-Whyte J, Lisbon A. Aspiration of gastric bacteria in antacid-treated patients: A frequent cause of postoperative colonisation of the airway. Lancet 1982;1:242-245.
16. O'Keefe GE, Gentilello LM, Maier RV. Incidence of infectious complications associated with the use of histamine2-receptor antagonists in critically ill trauma patients. Ann Surg 1998;227:120-125.
17. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients: Resolving discordant meta-analyses. JAMA 1996;275:308-314.
18. Murray BE. New aspects of antimicrobial resistance and the resulting therapeutic dilemmas. J Infect Dis 1991;163:1185-1194.
19. Davies BI, Maesen FPV, Gubbelmans R. Azithromycin (CP-62,993) in acute exacerbations of chronic bronchitis: An open clinical, microbiological and pharmacokinetic study. J Antimicrob Chemother 1989;23:743-751.
20. Schito GC, Mannelli S, Pesce A, and The Alexander Project Group. Trends in the activity of macrolide and β-lactam antibiotics and resistance development. J Chemother 1997;9(suppl 3):18-28.
21. Jacobs MR, Bajaksouzian S, Lin G, Appelbaum PC. Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to oral agents: Results of a 1997 epidemiological study. Presented at the 98th General Meeting of the American Society for Microbiology; May 17-21, 1998; Atlanta, GA. [Abstract A-31].
22. Ronchetti MP, Zilles A, Appelbaum PC, Jacobs MR. Susceptibility of current and archived otitis media isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to contemporary oral agents. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; September 24-27,1998, San Diego, CA. [Abstract E-9].
23. Jones RN. Can antimicrobial activity be sustained? An appraisal of orally administered drugs used for respiratory tract infections. Diagn Microbiol Infect Dis 1997;27:21-28.
24. rd ed Montvale, NJ: Medical Economics Co; 1999:649.
25. Davidson M, Parkinson AJ, Bulkow LR, Fitzgerald MA, Peters HV, Parks DJ. The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990: Ethnic differences and opportunities for prevention. J Infect Dis 1994;170:368-376.
26. Centers for Disease Control and Prevention. Pneumococcal and influenza vaccination coverage levels among adults aged greater than or equal to 65 years: United States, 1993. Morb Mort Wkly Rep 1996;45:853-859.